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A simple, economic, green, and sensitive bioanalytical method for empagliﬂozin bioassay in rats’ plasma was employed successfully owing to the empagliﬂozin native ﬂuorescence behavior. Enhanced liquid-liquid extraction, using diethyl ether (DEE),
was successfully employed for the improved extraction of empagliﬂozin from rats’ plasma based on its high value of logP as 1.8
that boosted the drug migration from plasma to the organic layer. The relative ﬂuorescence intensity for empagliﬂozin was
recorded at emission (299.4 nm) after excitation at 226.5 nm. The method was validated with satisfactory results for linearity
(500–5000 ng/mL), trueness, precision, the matrix eﬀect, and extraction recovery. The matrix eﬀect ranged between 15.63% and
23.10% for LQC and HQC samples, respectively. Extraction recovery ranged between 54.61% and 62.54% for LQC and HQC
samples, respectively. Bias values for the trueness ranged between −10.62 and +14.95, while %RSD values for the precision ranged
between 5.39% and 9.33%. The method was successfully applied to rats’ plasma samples that included six rats, and the drug
concentration was determined in their plasma after 1 hour (estimated Cmax based on literature) following oral administration of
empagliﬂozin with a concentration of 10 mg/Kg, p.o.. The developed cost-eﬀective spectroﬂuorimetric method in the present work
will be of beneﬁcial use in further pharmacokinetic studies that include rats’ plasma and biological ﬂuids. Moreover, with the
suitable modiﬁcations, the described novel extraction of empagliﬂozin could be adopted to human plasma samples and future
clinical studies. Moreover, development of new simple cost-eﬀective methods is necessary to give the researchers a set of
“varieties” that they can use according to the laboratory limitations, especially in the developing countries in addition of being a
greener method due to the lower consumption of toxic solvents and lower waste production.

1. Introduction
Type 2 diabetes is increasing in predominance worldwide
with its major serious complications despite the diverse
therapeutic strategies. Furthermore, the foremost cause of
morbidity and mortality for the type 2 diabetes patients is
due to cardiovascular diseases [1, 2]. Sodium glucose linked
transporter 2 inhibitors (SGLT2i) are cutting edge class of

drugs for the management of type 2 diabetes proposing an
original insulin-independent mechanism for reﬁning the
blood glucose levels [3, 4]. Empagliﬂozin (EFN) is one of the
highly speciﬁc SGLT2i that induces glycosuria. It improves
the blood glucose levels as an antidiabetic with promising
HbA1c reduction results over the long term, better bodyweight control, and signiﬁcant improvements in microvascular outcomes [5]. Moreover, EFN ameliorates
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endothelial dysfunction, reduces vascular damage and
progression of heart failure, and suppresses atherogenesis
with future considerations as a pluripotent drug [6, 7]. EFN,
used as a monotherapy or add-on therapy to other antihyperglycaemic drugs, is well tolerated and rapidly absorbed
following oral administration [8].
Many chromatographic methods with UV and mass
detection were reported for the assay of EFN in pharmaceutical dosage form and biological ﬂuids either alone or in
combination with linagliptin, metformin, and/or other
antidiabetics [9–26]. Yet, they lack of being simple, fast, and
cost-eﬀective approaches due to the required costly complex
instrumentation and time-consuming multipart analytical
procedures. In addition, a voltammetry method has been
reported for the analysis and bioanalysis of EFN in pharmaceutical dosage form and human urine [27]. Spectrophotometric and chemometric methods were reported for
EFN by the ﬁrst author [28], but those methods missed the
known higher sensitivity output of the spectroﬂuorometric
analysis. The purpose of the current investigation is to
provide a new greener bioanalytical method for the determination of EFN in rats’ plasma with full detailed validation
according to the FDA guidelines as an alternative for the
high cost methods described in the literature with the
possible reduced cost advantage.
Fluorescence is the most common and useful type of
photoluminescence in analytical chemistry. Spectroﬂuorometric technique exhibits extremely high sensitivity, which
can be applied to the detection of a very wide range of
analytes in environmental and biological samples, especially
in case of the native ﬂuorescence of the drug without the
need for the pretreatment derivatization or modiﬁcation. Its
capacity of detection is approximately one order of magnitude greater than that of molecular absorption spectroscopy, and its selectivity is clearly greater than that of other
spectroscopic methods. Accordingly, spectroﬂuorometry
has been applied for the analysis of diﬀerent analytes in
complex matrices [29–31]. Furthermore, in the developing
countries (that include Egypt), the application of spectroﬂuorometry in bioanalysis continues to be popular due to
the simplicity, the common availability of the instrumentation, and the low cost without the need of costly infrastructure that is not applicable in QC labs with limited fund.
Although two spectroﬂuorometric analytical procedures
were described for EFN [32, 33], one of them was based on
EFN derivatization before its determination in human
plasma [32], while the other synchronous method did not
consider its application to biological ﬂuids and/or rats’
plasma samples [33]. That deﬁnes the current study as the
“ﬁrst” spectroﬂuorometric method for EFN bioanalysis in
rats’ plasma based on its native ﬂuorescence. In the current
investigation, a simple spectroﬂuorometric method was
described for the accurate and precise determination of EFN
(Figure 1) in rats’ plasma. FDA guidelines [34] were applied
for the whole method development and bioanalytical validation including selectivity, linearity, trueness, interday and
intraday precision, dilution integrity, extraction recovery,
the matrix eﬀect, and stability studies. This study will be of
interest for pharmaceutical industry and researchers
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Figure 1: Chemical structure of empagliﬂozin (EFN).

working in the QC area of pharmaceutical analysis and
bioanalysis.

2. Materials and Methods
Shimadzu spectroﬂuorometer, RF-6000 model R928 photomultiplier, 3D measurement function, with 1 cm quartz
cuvettes (Kyoto, Japan), controlled from a PC using the Lab
Solution RF software for Windows (Rev.B.04.01, Shimadzu),
was used. The temperature of the sample cuvette while
taking measurement was left uncontrolled at room temperature. EFN certiﬁed to contain 99.7% and rats’ plasma
were “thankfully” supplied as a gift from the Center for Drug
Research and Development (CDRD, the British University
in Egypt). Analytical grade methanol was purchased from
Sigma Aldrich (Germany).
Standard stock solution of EFN (1 mg/mL) was prepared
in methanol; then, standard and quality control (QC)
working solutions with diﬀerent concentrations were prepared in methanol (100, 200, 400, 500, 600, 800, and 1000 µg/
mL). 10 μL of each one of the prepared working solutions
was used to spike 1990 μL blank plasma to prepare calibration and QC samples with ﬁnal concentrations of 500
(LQC), 1000, 2000, 2500 (MQC), 3000, 4000, and 5000
(HQC) ng/mL (for studying linearity, trueness, and
precision).
2.1. Regarding Spiked and Real Samples Preparation. Two
millilitres of rats’ plasma was liquid-liquid extracted using
6 mL of diethyl ether (and the whole method was repeated
with another 6 mL at the end), vortexed for 1 min, centrifuged for 30 min at 6000 rpm (2,817 × g), and freezed. Then,
the upper organic DEE layer was separated and evaporated
using a vacuum concentrator at 50°C for 20 min till dryness.
The EFN extracted samples were then reconstituted with
2 mL of methanol, vortexed, and then transferred into the
cuvette. The relative ﬂuorescence intensity for EFNextracted samples was recorded at λ emission (299.4 nm)
after λ excitation at 226.5 nm. The biological samples were
constantly maintained at −20°C until use, and the calibration
and QC samples were freshly prepared every day.
2.2. Regarding the Animal Study. Six Sprague–Dawley rats
received EFN (10 mg/Kg, p.o.) dissolved in saline and sodium lauryl sulphate as surfactant. It is worthy to mention
that using sodium lauryl sulphate was necessary because of
the high lipophilic nature of empagliﬂozin to ensure its
dissolution eﬃciently. One hour later (estimated Cmax
based on literature following oral administration in rats
[14]), blood samples were collected from the retroorbital
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plexus and treated with anticoagulant (heparin at a ﬁnal
concentration of 1 U/mL and EDTA at a ﬁnal concentration
of 1 mg/mL). Plasma (2 mL) was separated by centrifugation
at 1000 rpm (78 × g) for 10 min and then used for the assessment of the EFN level as described in the sample
preparation. EFN dose was calculated based on reported
doses and human to animal dose conversions with full
consideration to the diﬀerences in the surface area between
species [35]. This study was approved by the British University in Egypt Faculty of Pharmacy Ethical Committee
(code: EX-2008, approved on 9 December 2020). The
mentioned ethical committee is recognized by ENREC
(Egyptian Network of Research Ethics Committees), http://
www.enrec.org/directory. Finally, the extracted plasma
samples were frozen and stored until use.
2.3. Regarding Bioanalytical Method Validation and Stability
Studies. Bioanalytical method validation was achieved in
agreement with the FDA guidelines. The selectivity of the
method was evaluated by comparing the extracted EFN
emission spectra at 500 ng/mL with blank plasma. Six different batches of blank rats’ plasma (from 6 diﬀerent rats)
donated from CDRD-BUE were checked for interference as
a measure of selectivity. The linearity was detected using
calibration standard samples within the range of
500–5000 ng/mL. The relative ﬂuorescence intensity was
used against concentrations to predict the calibration curve
and the regression equation. EFN concentrations were
calculated using the corresponding regression equation to
check the trueness of the method. The trueness of the
method denoted the closeness of a measured value to the
actual one and was estimated as recovery percent (R%). To
check the precision displaying the closeness of multiple
samples measurements exhibiting the same concentration,
QC samples were assayed three times (n � 3) within the same
day to assess the intraday precision, while interday precision
was assessed on three successive days (n � 3). Both intraday
and interday percent relative standard deviations (%RSD)
were calculated. Moreover, the eﬀect of the matrix on the
response was computed as the ratio of the relative ﬂuorescence intensities arisen from recording the spectra of
postpreparation EFN-spiked samples to that of the corresponding neat solutions. The extraction recovery was
assessed from the ratio of the relative ﬂuorescence intensities
arisen from recording the spectra EFN spiked samples to the
postpreparation spiked samples.
Evaluating the small but deliberate changes that could
occur during the routine analysis was carried out through
the assessment of the method robustness. Robustness was
checked at 500 ng/mL through a slight variation in λ excitation at 226 nm and then by %RSD calculation. The dilution
integrity experiment for the rats’ plasma method was carried
out at 5 times and 10 times dilution of the high concentration samples (10 μg/mL), and the corresponding concentrations were calculated. The used high concentration
was higher than the upper limit of quantiﬁcation. The
percentage change from the comparison sample should be
within ±15%. Stability of LQC and HQC was estimated
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based on 4 diﬀerent bioassays after leaving the samples 3 h in
the cuvette or leaving them 3 h at room temperature (bench
top short-term stability) or analyzing them after three
complete cycles (each cycle for two weeks) of both freeze and
thaw. Finally, stability for the long-term stability was investigated by checking the samples after two weeks while
freezing at −80°C. The four adopted stability studies were
conducted as per FDA guidelines.

3. Results and Discussion
First, working on bioanalysis of recently approved antidiabetics provides valuable information about the behavior of
the drugs in biological ﬂuids either plasma samples or the
other biological tissues such as brain tissue and/or urine
samples. More applications could be developed using such
information (like logP and enhanced extraction, for example) with outstanding outcomes up to even the repurposing of the antidiabetic drug for other uses in case of BBB
crossing or other valuable behavior in biological ﬂuids [36].
The proposed spectroﬂuorometric method was eﬀectively
applied for the determination of EFN in rats’ plasma. To
achieve the highest sensitivity and the ﬁnest peak shape,
diﬀerent parameters were raised. Upon a 3D scan, wavelengths were denoted, and the emission spectrum was obtained by scanning the emission monochromator at various
λ emission, at a particular λ excitation. Eventually, the
ﬂuorescence intensity for EFN was best recorded at λ
emission (299.4 nm) after λ excitation at 226.5 nm as shown
in Figure 2. The scan speed, data interval, and the excitation
and emission bandwidths were 600 nm/min, 0.2, and 15 nm,
respectively. Moreover, among several tested diluting solvents, methanol showed the utmost relative ﬂuorescence
intensities [33].
Sample preparation had been enhanced to accomplish
adequate recovery and the matrix eﬀect. Studying EFN
polarity and XlogP3-AA (�2) [37], protein precipitation and
liquid-liquid extraction were evaluated for the plasma extraction. However, protein precipitation did not achieve the
anticipated recoveries. Protein precipitation reported
drawbacks [38], such as the long time taken for the evaporation and dryness phases, the quiet presence of remaining
impurities in the samples, and the further needed clean-up,
were inevitable in this study. While implementing the
preliminary investigations with the current spectroﬂuorometric approach, protein precipitation using acetonitrile (4
times the plasma volume) showed inaccurate determinations. Many nonlinear results and even interference from
blank plasma samples were noticed which may be attributed
to the EFN high logP value. Moreover, using perchloric acid
as the precipitating agent also failed to show satisfying
results.
Liquid-liquid extraction was successfully applied for
EFN plasma extraction achieving the best sensitivity, trueness, and recovery. It was assessed with diﬀerent solvents
such as ethyl acetate, DEE, and hexane and after the addition
of diﬀerent pH ranges buﬀers. Phosphate buﬀer (0.2 M, pH
3–10), acetate buﬀer (0.2 M, pH 3–5), and borate buﬀer
(0.2 M, pH 8–10) solutions were used with the diﬀerent
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Figure 2: Fluorescence intensity for neat sample of EFN (750 ng/
mL) in methanol at emission (299.4 nm) after excitation at
226.5 nm.

mentioned extracting solvents in a trial to enhance the
extraction procedure. Finally, the lower limit of quantiﬁcation (LLOQ) was identiﬁed using the DEE that provided
the cleanest extract and the highest recovery, while the other
solvents showed lower eﬃciency to extract EFN (using the
spectroﬂuorometric approach), while no diﬀerence was
noticed upon the buﬀer addition. Using ethyl acetate and
hexane showed the matrix eﬀect of 25% and 28%, respectively, and both are higher than the average matrix eﬀect
(19.4%) received from DEE. In addition, both ethyl acetate
and hexane showed recoveries below 50%, so they were
excluded from the extraction parameters, especially no
signiﬁcant diﬀerence was detected (2–4%) after the addition
of diﬀerent buﬀers (either phosphate or acetate or borate).
Consequently, liquid-liquid extraction, using DEE, was
successfully used for the enhanced extraction of EFN from
rats’ plasma based on its high value of logP as 1.8 that
enhanced the drug migration from plasma to the organic
layer.
The relative ﬂuorescence intensity for EFN was recorded
at λ emission (299.4 nm) after λ excitation at 226.5 nm.
Spectroﬂuorometric bioanalysis provides major advantages
over all the chromatographic methods in the literature that
include simplicity and the lack of need to prepare the stationary and mobile phases which is time consuming and
costly. Moreover, development of new simple cost-eﬀective
methods is necessary to give the researchers a set of “varieties” that they can use according to the laboratory limitations, especially in the developing countries in addition of
being a greener method due to the lower consumption of
toxic solvents and lower waste production.
The developed cost-eﬀective spectroﬂuorimetric method
in the present work will be of beneﬁcial use in further
pharmacokinetic studies that include rats’ plasma and biological ﬂuids. Moreover, with the suitable modiﬁcations,
the described novel extraction of EFN can be adopted to
human plasma samples and future clinical studies. The
developed assay was validated eﬃcaciously according to the
FDA guidelines [29]. Good linearity and results were obtained as shown in consecutive increase in the ﬂuorescence
intensity (Figure 3) before subtracting the blank value of the

240.0
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350.0

400.0
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Figure 3: Overlay of EFN calibrators (500–5000 ng/mL) at
emission (299.4 nm) after excitation at 226.5 nm before subtracting
the blank ﬂuorescence intensity to calculate the relative ﬂuorescence intensity for all samples.

blank plasma to calculate the relative ﬂuorescence intensity
and as per the following ﬁndings. The regression equation
was computed and found to be RFI � 4.0517 Conc. +3884,
r2 � 0.9928, and r � 0.9964, where RFI is the relative ﬂuorescence intensity, r2 is the regression coeﬃcient, and r is the
correlation coeﬃcient (Figure 4). LLOQ was found to be
500 ng/mL experimentally.
The method was validated with satisfactory results
enclosing linearity range (500–5000 ng/mL), trueness, precision, the matrix eﬀect, and extraction recovery. Relative
bias values for the trueness (relative diﬀerence than 100%
recovery) ranged between −10.62 and +11.70 for LQC, −7.4
and +5.69 for MQC, and 11.11 and 14.95 for HQC samples.
The percent relative standard deviation (% R.S.D.) values
for the precision of QC samples ranged between 5.83%
and 9.33% for the interday repeatability, while they ranged
between 5.39% and 6.85% for the intraday repeatability.
Extraction recovery ranged between 54.61% and 62.54%
for LQC and HQC samples, respectively, and the low
values of the extraction recoveries may be due to the
reported high binding of EFN to plasma proteins. Dilution
integrity showed satisfying recoveries either for the ﬁve
times or ten times dilution samples with bias below 5%,
and all stability samples showed recoveries more than
85%, and all these results are compatible with FDA
guidelines.
The inﬂuence of the matrix on the response was
evaluated, and the matrix eﬀect was consistent and ranged
between 15.63% and 23.10% for LQC and HQC samples,
respectively. Robustness was analyzed at 500 ng/mL with a
slight variation in λ excitation at 226 nm, and %RSD
showed no signiﬁcant diﬀerence. The low value of %RSD
reveals the eﬀective reliability, consistency, and robustness
of the adopted method. The method was successfully applied to biological samples that included six rats, and
plasma EFN concentration was determined one hour
(estimated Cmax based on literature [14]) after EFN administration (10 mg/Kg, p.o.). The mean and S.D. of the
biological samples’ concentration were 625.39 ng/mL and
262.48, respectively (Figure 5). The calculated mean

Relative ﬂuorescence intensity
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Figure 4: EFN calibrators (500–5000 ng/mL) at emission (299.4 nm) after excitation at 226.5 nm after subtracting the blank ﬂuorescence
intensity to calculate the relative ﬂuorescence intensity for all samples.
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Figure 5: Emission spectra of a biological sample at 299.4 nm after excitation at 226.5 nm after 1 hour (estimated Cmax based on literature
[14]) after oral administration of empagliﬂozin with a concentration of 10 mg/kg.

concentration in biological samples was found within the
developed calibration curve from the described underlying
investigation.

Data Availability
The data (including ﬁgures) used to support the ﬁndings of
this study are included within the article.

4. Conclusions
The simple validated and robust spectroﬂuorometric
method was proved to be suitable for EFN determination in
rats’ plasma using a one-step liquid-liquid extraction. The
developed cost-eﬀective bioanalytical method in the present
work disclosed good precision, trueness, and linearity, which
will be of beneﬁcial use in further pharmacokinetic and
preclinical studies. Spectroﬂuorometric bioanalysis provides
major advantages over all the chromatographic methods in
the literature that include simplicity and the lack of need to
prepare the stationary and mobile phases which is time
consuming and costly. Moreover, development of new
simple and cost-eﬀective methods is necessary to give the
researchers a set of “varieties” to be used according to the
laboratory limitations especially in the developing countries
in addition of being a greener method due to the lower
consumption of toxic solvents and lower waste production.
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Samples of empagliﬂozin are available from the CDRD
Research Center.
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